Objective To evaluate the comparability of erythrocyte sedimentation rate (ESR) between the Monitor‐20 automated ESR analyzer and manual Westergren method .Methods ESR of 50 clinic samples were detected by Monitor‐20 automated ESR an‐alyzer and Westergren method respectively ,and the results of ESR were compared analyzed .Results There there was no significant differences between ESR results detected by by Monitor‐20 automated ESR analyzer and Westergren method (t= 0 .4673 ,P> 0 . 05) .The satisfactory correlation was founded between the two method (r=0 .9890 ,P<0 .01) .Conclusion There may be a satisfac‐tory correlation between Monitor‐20 automated ESR analyzer and manual Westergren method in the determination of ESR .Monitor‐20 automated ESR analyzer could be a rapid ,precise ,accurate method in measuring ESR ,and could be worthy to extend the applica‐tion in clinic .

Objective To investigate the significance of single and combined detection of serum alpha1-antitrypsin,alpha1-acid glycoprotein and alpha-fetoprotein in the diagnosis of primary hepatic carcinoma(PHC).Methods Technique of rate nephelometry was used to detect the serum AAT and AAG in 58 PHC patients,47 patients with benign liver disease and 41 healthy people.The serum levels of AFP in the three groups were measured by chemiluminescence immunoassay.Results The levels of AAT,AAG and AFP in PHC group was higher than those in control group (P <0.05).The sensitivity of AAT,AAG and AFP in the diagnosis of PHC was 82.8%,84.5% and 72.4% respectively;The specificity was 85.2%,90.9% and 83.0% respectively.The combined measurement of the 3 makers could elevated the diagnostic specificity of PHC to 98.3%.Conclusion Detection of serum AAT and AAG can be a supplement to AFP.Combined measurement of the 3 makers might increase the diagnostic sensitivity of PHC.

Objective To observe the clinical efficacy of Oseltamivir combined with Chinese medicine for the treatment of influenza. Methods One hundred and ninety-seven cases confirmed as influenza were randomly divided into treatment group ( N=101) and control group ( N=96) . Both groups were given conventional symptomatic and supportive treatment. Additionally, the treatment group received Oseltamivir and Chinese medicine based on syndrome differentiation, and the control group was given Oseltamivir orally. The treatment lasted 5 days. The clinical outcomes included incidence of flu symptoms, time for body temperature decreasing to the normal and time for the relief of all symptoms in both groups. Results ( 1) The total effective rate of the treatment group was 98.0%, superior to 91.7%of the control group (P<0.05) . (2) The treatment group had an effect on sub-siding fever and relieving symptoms more quickly than the control group, the differences being significant (P<0.05 or P<0.01) . ( 3) The treatment group could relieve flu symp toms of sore throat, muscular soreness, cough, nasal obstruction and discharging more effectively, and the differences were significant compared with the control group (P<0.05) . Conclusion The overall effect of Oseltamivir combined with Chinese medicine is better than Oseltamivir alone, showing the advantages of subsiding fever in a relatively short period of time and relieving flu symptoms more effectively.

Lung cancer is the leading cause of cancer death worldwide. Significant advancements have been observed in the thera-py for non-small celllung cancer (NSCLC). With constant extension of new awareness regarding the histopathology of lung cancer, ho-mologous chemotherapeutic regimens have been developed on the basis of histopathological sub-typing methods. With developments in molecular biology, driving gene mutations during tumorigenesis and progression have been discovered. A series of targeted drugs for various molecular subtypes has also been investigated and developed on the basis of these mutations. This review summarizes recently published clinical outcomes on the management of advanced NSCLC and strategies to apply drugs in clinical treatments.

Malnutrition is the common complication for the patients with gastrointestinal neoplasms during perioperative period.Tumor and chemotherapy drugs are the main influencing factors of patients with malnutrition.The correct evaluation of the nutritional status in patients is the basis of individualized nutrition therapy.New evaluation methods and nutritional preparations could more help patients with gastrointestinal neoplasms during perioperative period to maintaining good nutritional status.

Objective To observed the analgesia and adverse reactions of continuous patients-controlled in-terscalene analgesia with patient-controlled intravenous analgesia for the shoulder arthroscopic surgery.Methods 40 patients with ASA Ⅰ ~Ⅱ anesthesia in general anesthesia for the shoulder arthroscopic surgery were selected and randomly divided into the two groups,20 cases in each group.They were continuous patients-controlled interscalene analgesia(PCNA)and patient-controlled intravenous analgesia (PCA).PCNA with 0.2% ropivacaine +saline to 100mL,background parameters 4ml/h,a single dose of 0.5mL,lock 20min.24 hours after dosing.PCA with fentanyl lmg +tropisetron 5mg +saline to 100mL,background parameters 2mL/h,a single dose of 3.5mL,lock 20min.Record the VAS score 6h,12h,24h,48h after surgery,and adverse side effects of postoperative dizziness,nausea,vomiting and itchy skin.And the patient's analgesic satisfaction survey 48h after surgery.Results PCNA after surgery 6h,12h, 24h,48h in VAS score was significantly lower than the PCA(P <0.05).PCNA were dizziness,nausea,vomiting and the incidence is lower than the PCA,the difference was statistically significant(P <0.05).The PCNA of patients sat-isfaction was 100%,the PCA of patients satisfaction is 75%,the difference was statistically significant(P <0.05). Conclusion In the postoperative analgesia of shoulder arthroscopic surgery,the analgesic effect and patient satisfac-tion of continuous patients-controlled interscalene analgesia are better than patient-controlled intravenous analgesia. And the dizziness,nausea,vomiting is lower.

Background Rabbits are commonly used as animal models for the evaluation of drugs and surgery to lower intraocular pressure (IOP).The accuracy of IOP measurement is therefore critical in the analysis of data and subsequent extrapolation to humans.An accurate method to measure rabbit IOP is intracameral manometry,but it is an invasive way.Schi(o)tz,Perkins and Rebound were often used in clinic.However,their accuracy in measuring rabbit IOP in experimental study is unclear.Objective The purpose of this study was to investigate the accuracy of IOP measured by Schi(o)tz tonometer,Perkins tonometer and Rebound tonometer relative to intracameral manometry in New Zealand white rabbits.Methods The central corneal thickness (CCT),corneal curvature (CC),axial length (AL),anterior chamber depth (ACD),lens thickness (LT) and scleral thickness (ST) were respectively measured in 8 eyes of 8 healthy New Zealand white rabbits with lenstar900 and ultrasound biomicroscopy (UBM).The actual IOP was measured with a 24G needle inserted the anterior chamber and connected to a pressure transducer under the general anesthesia,the IOP gradient was set with a 24G needle inserting the vitreous cavity and connecting to a container with balanced salt solution(BSS).Then,comparative measurements at the same pressures were performed with three types of tonometers.The IOP values from Schi(o)tz tonometer,Perkins tonometer and Rebound tonometer were calibrated based on actual IOP from intracameral manometry and eyeball physiological parameters by multiple regression equation.Results The mean of CCT,CC,AL,ACD,LT and ST was (338.96 ±21.52) μm,(51.68±1.66) D,(14.63±0.19) mm,(2.22±0.04) mm,(6.15±0.10) mm and (339.80±47.41) μm.Compared with the intracameral manometry value (IMV),the error range was (17.08± 11.22) mmHg in the Schi(o)tz tonometer value (STV),(25.81±12.43) mmHg in the Perkins tonometer value (PTV) and (22.50±11.47) mmHg in the Rebound tonometer value (RTV),with significant differences between them (t =10.54,14.39,13.59,all at P＜ 0.05).Compared with IMV,the 95％ limits of agreement of three portable tonometer values is larger,and three portable tonometer values had the greater measurement error with elevated IOP gradient.The regression equations was IOP =141.015 + 1.570 × STV + 0.122 × CCT-3.480 × CC between actual IOP and STV (R =0.92,P =0.00),IOP =-33.323+1.914×PTV+0.133×CCT between actual IOP and PTV(R =0.88,P=0.00),IOP=160.395+1.866×RTV+ 0.201×CCT+34.554×LT-2.649×CC+0.063×ST between actual IOP and RTV (R=0.95,P=0.00).Conclusions The physiological parameters of rabbit eyeball are obviously different from human.The STV,PTV and RTV have a great measuring error in comparson with actual IOP,and therefore it is necessary to correct STV,PTV and RTV based on the ocular physiology parameters in experimental study.

Purpose:The phase I study was conducted to evaluate the maximum tolerated dose (MTD) and toxicity of weekly administered docetaxel combined with cisplatin in patients with non-small cell lung cancer ( NSCLC ). The other objective was to measure the pharmacokinetic/dynamics (PK/PD).Methods:In the dose escalation study, 15 patients with unresectable and metastatic untreated NSCLC with performance status(0-1) were enrolled. Escalating doses of D 25 mg/m 2 (30 mg/m 2, 35 mg/m 2, 40 mg/m 2) on day 1, 8, 15 were given as a 30 min iv infusions and C 75 mg/m 2 30 min iv infusion after D on day 1 and the cycle was repeated every 4 weeks. Blood samples were drawn on day 1 and 15 in the first cycle to measure the PK. Dose limiting toxicity(DLT) was based on Cycle 1 and defined as any Grade 3 non-hematologic toxicity not declining to Grade 2 or less within 4 days or any Grade 4 toxicity. Results:Chemotherapy was repeated for at least two cyc1es every 28 days. All patients were assessable for toxicities. Although grade 3/4 neutropenia occurred, there were no significant modifications of chemotherapy schedule. One patient developed an infection (DLT). Non-hematological toxicities, including nausea/vomiting, a1opecia, fluid intension and asthenia were tolerable. Based on these data, the MTD has not yet reached up to dose level of docetaxel of 40mg/m 2 weekly given in combination with cisplatin 75mg/m 2 every 4 weeks at the fixed dose. The exposure to docetaxel after Ⅳ administration on day 1 in combination with cisplatin and on day 15 without cisplatin , increased proportional to the dose for the range 25 to 40 mg/m 2, as measured by Cmax and AUC. No statistically significant difference between clearance values was shown for the 4 dose levels. The pharmacokinetics of docetaxel was not influenced by the coadministration of cisplatin on day 1 as compared to day 15, as the CmaxN, AUCN and CL were not statistically significantly different on both days. Fourteen patients were eva1uab1e for response, five cases achieved partial response, and thus the overall response was 35.7%. 1, 2, and 3 year survivals were 73%, 27%, and 20%, respectively. Weekly administration of docetaxel at 35mg/m 2 (days 1, 8, l5) combined with cisplatin 75mg/m 2 (day 1) is recommended for phase Ⅱ studies. Conclusions:Using the weekly schedule, toxicity was mainly manifested by non-hematologic profile and was well tolerated. A phase Ⅱ study is currently ongoing with docetaxel 35mg/m 2 as the suggested dosage.

Purpose:To study the efficacy and safety of docetaxel administrated weekly plus cisplatin in the treatment for patients with advanced non-small-cell lung cancer (NSCLC). Methods:Thirty-six patients with stage ⅢB,stage Ⅳ not treated previously by chemotherapy,or recurrenct after operation NSCLC received intravenous infusions of docetaxel at 35mg/m 2 three consecutive weeks,followed by a week of rest;and intravenous infusions of cisplatin at 75 mg/m 2 every four weeks. Results:There were 12 partial responses for an objective response rate of 33 %. The median survival was 11.5 months (range 4-27 months),and the 1-year survival was 50%. Hematologic toxicities,which were mild,included grade Ⅲ/Ⅳ neutropenia in 22%. The common nonhematologic toxicities included grade 2-3 nausea and vomiting (39%) and grade 2-3 asthenia (36%). Conclusions:Consecutive weekly administrations of docetaxel for 3 weeks plus cisplatin produce minimal myelosuppression and shows activity in the treatment of patients without previous chemtherapy with advanced NSCLC.

Objective To investigate the expression of thanatos-associated protein-8 (THAP-8) in ovarian cancer tissue,and explore its clinical significance.Methods A total of 86 patients with ovarian cancer were enrolled.The gene and protein expression of THAP-8 of the ovarian cancer tissue and adjacent tissue were detected by fluorescent quantitation polymerase chain reaction and immunohistochemistry.Results The gene expressions of THAP-8 of ovarian cancer tissue and adjacent tissue were 0.304 ± 0.104 and 0.615 ± 0.152.The protein expressions of THAP-8 in ovarian cancer tissue and adjacent tissue were 30.16 ± 12.34 and 67.34 ± 22.37.The gene and protein expressions of THAP-8 in ovarian cancer tissue were significantly lower than those in adjacent tissue (P＜ 0.01).The gene and protein expressions of THAP-8 in the low and middle degree of tumor differentiation of ovarian cancer tissue were significantly lower than those of the high degree of tumor differentiation of ovarian cancer tissue (0.216 ±0.085 vs.0.457 ±0.124 and 24.22 ± 9.21 vs.46.24 ± 17.52,P ＜ 0.01 or ＜ 0.05).The gene and protein expressions of THAP-8 in lymph node metastasis of ovarian cancer tissue were significantly lower than those of no lymph node metastasis of ovarian cancer tissue (0.247 ± 0.087 vs.0.476 ± 0.133 and 23.44 ± 8.57 vs.49.60 ± 18.35,P ＜ 0.01 or ＜0.05).The gene and protein expressions of THAP-8 in clinical TNM pathologic Ⅲ,Ⅳ stage of ovarian cancer tissue were significantly lower than those of Ⅰ,Ⅱ stage of ovarian cancer tissue (0.232 ± 0.114 vs.0.424 ±0.125 and 25.64 ±8.12 vs.44.78 ± 16.84,P ＜0.05).Conclusions The downregulation-expression of THAP-8 has a closed relationship with the development of ovarian cancer.The THAP-8 might be used as a potential marker to assess the degree of rumor grade and prognosis in ovarian cancer.